Alan Irvine, MD, DSc

home / authors / alan-irvine-md-dsc

Articles

Assessing Quality of Life and AAD Research Considerations

April 12th 2024

Alan Irvine, MD, DSc, shares insights on the impact of ruxolitinib on quality of life in pediatric patients and 2024 AAD research presentations to take into consideration.

Observing BSA Changes and Inflammation Resolution

Alan Irvine, MD, DSc

April 12th 2024

Alan Irvine, MD, DSc, offers an understanding of BSA changes and anti-inflammatory effects of ruxolitinib in the latest research presented.

Alan Irvine, MD, DSc: Atopic Dermatitis and the Biological Clock

Emma Andrus, Associate Editor;Alan Irvine, MD, DSc

December 10th 2023

Alan Irvine, MD, DSc, discusses his Revolutionizing Atopic Dermatitis session and exciting advances in AD.

Latest Updated Articles

Published: September 19th 2024 | Updated: September 26th 2024

Final Thoughts: The Importance of Comparative Studies in AD

Published: December 16th 2024 | Updated: December 18th 2024

The Burden of Prurigo Nodularis

Published: December 16th 2024 | Updated: December 18th 2024

ICYMI: FDA Approves Galderma's Nemolizumab for Moderate to Severe Atopic Dermatitis in Patients 12 and Older

Published: December 16th 2024 | Updated: December 18th 2024

FDA Approves Tapinarof Cream, 1% for Atopic Dermatitis in Patients 2 Years and Older

Published: December 16th 2024 | Updated: December 18th 2024

Arcutis Submits sNDA for Roflumilast Cream 0.05% to FDA for Patients Ages 2 to 5 with Atopic Dermatitis

Published: December 13th 2024 | Updated: December 18th 2024

2024 Key Insights: Psoriasis

About

Advertise

Job Board

Do Not Sell My Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777